As of May, 14 Alimera Sciences, Inc. (ALIM) Analysts See $-0.04 EPS

April 17, 2018 - By Michele Cranor

Alimera Sciences, Inc. (NASDAQ:ALIM) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 1. That’s change of 0.64, from 2017Q3’s 1.64. 4 investors sold all, 8 reduced holdings as Alimera Sciences, Inc. ratio dropped. 9 increased stakes while 3 funds bought stakes. Funds hold 28.68 million shares thus 0.99% more from 2017Q3’s 28.40 million shares.
210,886 were accumulated by Blackrock. Prelude Capital Mngmt Ltd has invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Shufro Rose & Lc owns 10,000 shs or 0% of their US capital. Moreover, Orbimed Advsrs Ltd has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM). 20,056 were reported by Goldman Sachs Grp. Venbio Select Advisor Limited Liability holds 0.54% or 6.24 million shs. Barclays Public Limited Liability Company reported 93 shs. Two Sigma Secs Limited Liability Corp has invested 0% of its capital in Alimera Sciences, Inc. (NASDAQ:ALIM). Strs Ohio holds 0% of its capital in Alimera Sciences, Inc. (NASDAQ:ALIM) for 43,569 shs. Renaissance Ltd invested in 416,400 shs or 0% of the stock. Northern Tru, Illinois-based fund reported 102,791 shs. 31,500 were reported by Livingston Gp Asset Management (Operating As Southport Cap Management). Millennium Mgmt Ltd Liability invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Armistice Cap Limited Liability Corp reported 0.9% in Alimera Sciences, Inc. (NASDAQ:ALIM). Palo Alto Investors Limited Liability Company invested in 0.17% or 3.01M shs.

Alimera Sciences, Inc. had 10 sales and 1 insider buy since January 16, 2018. This’s net activity of $290,803. On Thursday, January 18 Shares for $63,379 were sold by Myers C. Daniel. On Tuesday, January 16 Shares for $14,181 were sold by Green Kenneth. EISWIRTH RICHARD S JR sold 14,494 shs worth $17,890. Ashman Philip sold $30,552 worth of Alimera Sciences, Inc. (NASDAQ:ALIM) on Thursday, January 18. $22,800 worth of Alimera Sciences, Inc. (NASDAQ:ALIM) was bought by ARMISTICE CAPITAL – LLC.

Alimera Sciences, Inc. (NASDAQ:ALIM) is expected to reveal earnings on May, 14., according to Faxor. EPS of $-0.04 is 60.00 % up from 2017’s $-0.1 EPS. Analysts at Wall Street see Alimera Sciences, Inc.’s -60.00 % EPS growth compared to $-0.10 EPS for last quarter. ALIM reached $1.12 on during the last trading session after $0.02 change.Alimera Sciences, Inc. has volume of 129,056 shares. Since April 17, 2017 ALIM has declined 28.28% and is downtrending. ALIM underperformed the S&P 500 by 39.83%.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally.The firm is worth $78.38 million. It focuses on diseases affecting the back of the eye or retina.Currently it has negative earnings. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Alimera Sciences, Inc. (NASDAQ:ALIM) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.